I don't think CYDY is "about to be worth" anything unless and until there is partnership or buyout. And as for partnership, I don't think your thought makes sense, that partner ship (sic) "would make sense if it were for all indications." That's called a buyout. CYDY has no leverage whatsoever and management knows it's time to move things in a different direction.

The company is out of money, has no CEO, and the current management suite is built to move the IP, not built to conduct trials. Deal makers have been brought in and are hopefully doing their best to bring us an outcome that we'll all do well with, maybe as well as we hoped, maybe not, but we'll mostly likely all be in the black and maybe, just maybe, leronlimab will be brought to the masses.